Le Lézard
Classified in: Health, Covid-19 virus
Subjects: MAV, POL, CFG

Notice To The Media - Ministers and Government of Canada officials to hold a news conference on coronavirus disease (COVID-19)


OTTAWA, March 22, 2020 /CNW/ - Ministers and Government of Canada officials will hold a news conference to provide an update on coronavirus disease (COVID-19).

Date
March 22, 2020

Time
12:00 PM (EDT)

Location
West Block, Room 225
Parliament Hill
Wellington Street, Ottawa, Ontario

The media availability will also be held by teleconference.
Toll-free (Canada/US) dial-in number: 1-866-206-0153
Passcode: 1622050#

Twitter:  @GovCanHealth
Facebook: Healthy Canadians

SOURCE Public Health Agency of Canada


These press releases may also interest you

at 08:05
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
Gilead Sciences, Inc. and Arcus Biosciences, Inc. today announced new data from Cohort B of ARC-9, a Phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a dual A2a/b adenosine receptor antagonist, plus anti-PD-1 monoclonal antibody...

at 08:05
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
Detailed positive results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of...

at 08:05
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
Detailed positive results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to...

1 jun 2024
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
Long-Term Follow-Up Data Signal Promising Progression-Free Survival (PFS) for Selinexor in the Maintenance Setting with Median PFS of 28.4 Months in the TP53 Wild-Type and 39.5 Months in the Proficient Mismatched Repair Status (pMMR) TP53 Wild-Type...

1 jun 2024
Taseko Announces that Operations at its Gibraltar Mine have been Suspended
Taseko Mines Limited (LSE: TKO) ("Taseko" or the "Company") announced today that operations at the Company's Gibraltar Mine have been suspended. Collective bargaining with Gibraltar's union representatives has been ongoing in recent weeks, and...

1 jun 2024
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
Takeda (TSE:4502/NYSE:TAK) and Pfizer today announced that the German Hodgkin Study Group (GHSG) will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® (brentuximab vedotin) in combination with chemotherapy as a late-breaking...

More news about Covid-19 virus...


News published on and distributed by: